“By enacting SB 671, Gov. Jerry Brown and California legislators are demonstrating their commitment to both patient health and fiscal health in their state,” Chip Davis, GPhA President and CEO, said. “This bill allows for substitution of interchangeable biologics and avoids measures that would hinder timely patient access to these products.”
Biosimilars are drugs engineered with properties similar to drugs that already have been licensed.
This year, 11 states have passed legislation that allows pharmacies to sell biosimilars, and the first biosimilar recently was approved for use in the U.S.
“With billions of dollars in health savings at stake for the nation’s patients, it is vital to make sure that the legal and regulatory framework enables competition and provides for timely access to safe, effective and more-affordable therapies,” Davis said.
GPhA represents manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. More information is available at www.gphaonline.org.
GPhA is the nation’s leading trade association for manufacturers and distributors of generic prescription drugs, manufacturers of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic industry.
Alerts Sign-up